Roche takes Tecentriq hit on survival data [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
Roche takes Tecentriq hit on survival data | Reuters 3 Min Read ZURICH (Reuters) - Roche’s hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck. Tecentriq, mixed with chemotherapy, has not yet achieved a hoped-for overall survival target in first-line non small cell lung cancer treatment, the Swiss drugmaker said on Thursday, though the cocktail did reduce risks of the disease worsening. Overall survival is the gold standard for judging a medicine’s effectiveness, but Roche now must wait until at least next year to show Tecentriq plays a significant role in keeping patients alive. In contrast, Merck’s Keynote-189 study demonstrated its Keytruda plus chemotherapy improved survival in newly-diagnosed patients. That leaves Tecentriq, with sales just a fraction of Keytruda’s and Bristol-Myers Squibb’s Opdivo, an also-ran i
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- TME Pharma Publishes 2023 Financial Results and Provides Operating Update [Yahoo! Finance]Yahoo! Finance
- Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat [Yahoo! Finance]Yahoo! Finance
- Scholz Gets Another Pharma Boost With New Merck KGaA Site [BNN Bloomberg (Canada)]BNN Bloomberg
- WebMD Ignite Unveils HealthHub Interactive to Support Health Plans' Clinical Programs [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers posts Q1 beat despite growth headwinds [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website